Multi-Marker Approach with the Use of Biochip Cardiac Array Technology for Early Diagnosis in Patients with Acute Coronary Syndromes.
BACKGROUND
Diagnosis of acute coronary syndrome (ACS) is frequently a challenging task while immediate risk stratification remains crucial for the prompt implementation of appropriate therapy in this setting. The prolonged release pattern of both CK-MB mass and cardiac troponins makes it difficult to identify the origin of recent chest pain, thus a combination of early and later biomarkers might further facilitate the differential diagnosis. The study was designed to evaluate the efficacy of multi-marker approach using biochip array technology in identifying ACS shortly after the symptom onset.


METHODS
The study group consisted of 42 patients suspected for ACS. Subjects were diagnosed as presenting with unstable angina (UA), non-ST-elevation myocardial infarction (NSTEMI) or ST-elevation myocardial infarction (STEMI). Biomarkers in the serum were determined twice: on admission (≤6 hours from the chest pain onset) and after next 6 hours. Cardiac troponin I was measured by routine sensitive automated assay (STAT cTnI) while other 6 cardiac markers (heart-fatty acid binding protein - H-FABP, myoglobin, glycogen phosphorylase BB, cTn I, CK-MB mass and carbonic anhydrase III) were assessed using biochip array technology.


RESULTS
STAT cTnI concentrations within 6 hours from the symptom onset were elevated over the 99(th) percentile for reference population in 83.3% of subjects but none reached the cut-off value for myocardial infarction. Instead, H-FABP demonstrated a very good efficacy in early detection of ACS (90.5%), better than myoglobin and CK-MB mass. Sensitivity of H-FABP calculated for NSTEMI/STEMI subjects reached 100%. The diagnostic efficacy of troponin, myoglobin and CK-MB mass assay markedly increased within 12 hours. It was only for the patients with UA that the cardiac panel was not efficient in the early stratification of risk.


CONCLUSIONS
A multi-marker strategy with H-FABP and highly sensitive troponin included enhances the early diagnosis and decision making process in patients with ACS. A new biochip cardiac array technology may serve as a powerful tool for ACS detection in the clinical practice.
Department of Laboratory Medicine, University of Nicolaus Copernicus , Bydgoszcz, Poland.
Marcin
M
Sawicki
Department of Laboratory Medicine, University of Nicolaus Copernicus , Bydgoszcz, Poland.
Grazyna
G
Sypniewska
Department of Laboratory Medicine, University of Nicolaus Copernicus , Bydgoszcz, Poland.
Magdalena
M
Krintus
Department of Cardiology and Internal Medicine, Collegium Medicum, University of Nicolaus Copernicus , Bydgoszcz, Poland odes@cm.umk.pl.
Marek
M
Kozinski
Department of Cardiology and Internal Medicine, Collegium Medicum, University of Nicolaus Copernicus , Bydgoszcz, Poland odes@cm.umk.pl.
Joanna
J
Ostrowska-Nowak
Department of Cardiology and Internal Medicine, Collegium Medicum, University of Nicolaus Copernicus , Bydgoszcz, Poland odes@cm.umk.pl.
Marta
M
Pilaczyńska-Cemel
Department of Cardiology and Internal Medicine, Collegium Medicum, University of Nicolaus Copernicus , Bydgoszcz, Poland odes@cm.umk.pl.
Dominika
D
Budzbon
Department of Cardiology and Internal Medicine, Collegium Medicum, University of Nicolaus Copernicus , Bydgoszcz, Poland odes@cm.umk.pl.
Kubica
K
Jacek
Eur J Emerg Med. 2008 Jun;15(3):140-4
18460953
Clin Chem Lab Med. 2006;44(11):1383-5
17087655
Scand Cardiovasc J. 2003;37(1):23-9
12745799
Clin Chem Lab Med. 2000 Mar;38(3):231-8
10905760
Circulation. 2006 Aug 8;114(6):550-7
16880323
Clin Chim Acta. 2007 May;381(1):14-20
17400202
Clin Chem. 2005 Aug;51(8):1397-404
15951316
Clin Chem. 1996 Jan;42(1):107-9
8565206
Prog Lipid Res. 1996 Sep;35(3):243-82
9082452